FrancophonIA/ELRC3.0 huggingface dataset:
English: LIFMIOR in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate.
Slovenian: Zdravilo LIFMIOR je v kombinaciji z metotreksatom indicirano za zdravljenje zmernega do hudega aktivnega revmatoidnega artritisa pri odraslih, kadar odziv na zdravljenje z imunomodulirajočimi antirevmatičnimi zdravili, vključno z metotreksatom (če ta ni kontraindiciran), ni zadosten.
English: LIFMIOR powder for solution must be reconstituted in 1 ml of solvent before use (see section 6.6).
Slovenian: Pred uporabo je treba LIFMIOR prašek za raztopino za injiciranje rekonstituirati v 1 ml vehikla (glejte poglavje 6.6).
English: The primary measure of efficacy (ASAS 20) was a ≥20% improvement in at least 3 of the 4 Assessment in Ankylosing Spondylitis (ASAS) domains (patient global assessments, back pain, BASFI, and inflammation) and absence of deterioration in the remaining domain.
Slovenian: Primarno merilo učinkovitosti (ASAS 20) je bilo  20 % izboljšanje pri vsaj 3 od 4 domen lestvice Ocenjevanje pri ankilozirajočem spondilitisu (ASAS - Assessment in Ankylosing Spondylitis) (bolnikova splošna ocena, bolečina v hrbtenici, BASFI in vnetje) ter odsotnost poslabšanja pri četrti domeni.
English: The differences in TSS and JSN were not statistically significant between methotrexate and LIFMIOR 25 mg.
Slovenian: Razlike v ocenah TSS in JSN med metotreksatom in 25 mg zdravila LIFMIOR niso bile statistično pomembne.
English: In adults (aged 18 and over), LIFMIOR can be used for moderate or severe rheumatoid arthritis, psoriatic arthritis, severe axial spondyloarthritis including ankylosing spondylitis, and moderate or severe psoriasis - in each case usually when other widely used treatments have not worked well enough or are not suitable for you.
Slovenian: Pri odraslih (starih 18 let in več) se zdravilo LIFMIOR lahko uporablja pri zdravljenju zmernega ali hudega revmatoidnega artritisa, psoriatičnega artritisa, hudega aksialnega spondilartritisa, vključno z ankilozirajočim spondilitisom, in zmerne ali hude luskavice - v vseh primerih običajno šele po neuspešnem zdravljenju z drugimi običajnimi oblikami zdravljenja, ali če te oblike zdravljenja za vas niso primerne.
English: Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.
Slovenian: Zdravljenje poliartritisa (pozitivnega ali negativnega za revmatoidni faktor) in razširjenega oligoartritisa pri otrocih in mladostnikih, starih 2 leti ali več, ki so se nezadostno odzvali na zdravljenje z metotreksatom ali ga niso prenašali.
English: The primary efficacy endpoint in all four studies was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75% improvement in the Psoriasis Area and Severity Index score from baseline) at 12 weeks.
Slovenian: Primarni opazovani dogodek učinkovitosti v vseh štirih študijah je bil tisti delež bolnikov v vsaki zdravljeni skupini, ki je po 12 tednih dosegel PASI 75 (tj. vsaj 75 % izboljšanje indeksa PASI - Psoriasis Area and Severity Index; indeks površine in izrazitosti psoriaze - v primerjavi z izhodiščem).
English: Withdrawing the LIFMIOR solution from the vial f.
Slovenian: Jemanje raztopine zdravila LIFMIOR iz viale f.
English: Clean the injection site with the alcohol swab using a circular motion, and allow it to dry.
Slovenian: Mesto injiciranja s krožnim gibom obrišite z alkoholno blazinico in pustite, da se posuši.
English: 4 vials of powder
Slovenian: 4 viale s praškom
English: Developmental toxicity studies performed in rats and rabbits have revealed no evidence of harm to the foetus or neonatal rat due to etanercept.
Slovenian: Študije toksičnosti za razvoj, ki so jih opravili na podganah in kuncih, niso pokazale nobenih znakov škodljivih učinkov etanercepta na zarodke ali novorojene podgane.
English: If you have any questions, please talk to a doctor, nurse or pharmacist who is familiar with LIFMIOR.
Slovenian: Če imate kakršnakoli vprašanja, se posvetujte z zdravnikom, medicinsko sestro ali farmacevtom, ki dobro poznajo zdravilo LIFMIOR.
English: †Please see sub-section ‘Undesirable effects in paediatric patients with juvenile idiopathic arthritis' above.
Slovenian: *glejte Opis izbranih neželenih učinkov v nadaljevanju prosimo, glejte podpoglavje ''Neželeni učinki pri otrocih z juvenilnim idiopatskim artritisom'' zgoraj
English: The efficacy of LIFMIOR was assessed in a randomised, double-blind, placebo-controlled study in 205 patients with psoriatic arthritis.
Slovenian: Učinkovitost zdravila LIFMIOR je bila ocenjena v randomizirani, dvojno slepi in s placebom nadzorovani študiji pri 205 bolnikih s psoriatičnim artritisom.
English: Patients with a significant exposure to varicella virus should temporarily discontinue LIFMIOR therapy and be considered for prophylactic treatment with Varicella Zoster Immune Globulin.
Slovenian: Bolniki, ki so zelo izpostavljeni virusu noric, naj začasno prekinejo zdravljenje z zdravilom LIFMIOR, v poštev pa pridejo tudi za profilaktično zdravljenje z imunoglobulinom proti virusu varicella-zoster.
English: Combining the results of controlled clinical trials, more cases of NMSC were observed in patients receiving LIFMIOR compared with control patients, particularly in patients with psoriasis.
Slovenian: Pri združevanju rezultatov nadzorovanih kliničnih preskušanj so opazili več primerov NMSC pri bolnikih, ki so prejemali zdravilo LIFMIOR, kot pri kontrolnih bolnikih, še zlasti pri bolnikih s psoriazo.
English: 4 years.
Slovenian: 4 leta
English: Adjusted mean change from baseline was 3.8 for LIFMIOR treated (n=95) versus 0.8 for placebo treated (n=105) patients (p<0.001).
Slovenian: Prilagojena povprečna sprememba od izhodišča je bila 3,8 pri bolnikih, zdravljenih z zdravilom LIFMIOR (n = 95), in 0,8 pri bolnikih, ki so prejemali placebo (n = 105) (p < 0,001).
English: For patients who received 50 mg once weekly throughout the study, the efficacy responses continued to improve with 71% achieving PASI 75 at week 24.
Slovenian: Pri bolnikih, ki so dobivali 50 mg enkrat na teden ves čas študije, so se odzivi glede učinkovitosti še naprej izboljševali, tako da je v 24. tednu PASI 75 doseglo 71 % bolnikov.
English: It is recommended that the conduct of these tests should be recorded in the patient's alert card. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.
Slovenian: Zdravnike predpisovalce opominjamo na nevarnost lažno negativnih rezultatov tuberkulinskega kožnega testa, še zlasti pri bolnikih, ki so hudo bolni ali imunoinkompetentni.
English: There were no differences in rates of infection among patients treated with LIFMIOR and those treated with placebo for plaque psoriasis in placebo-controlled trials of up to 24 weeks duration.
Slovenian: V stopnjah pogostnosti okužb med bolniki, zdravljenimi z zdravilom LIFMIOR, in tistimi, ki so prejemali placebo za zdravljenje psoriaze v plakih, v preskušanjih, nadzorovanih s placebom, ki so trajala do 24 tednov, ni bilo razlik.
English: Serious infections (including pneumonia, cellulitis, arthritis bacterial, sepsis and parasitic infection)*
Slovenian: resne okužbe (vključno s pljučnico, celulitisom, bakterijskim artritisom, sepso in parazitsko okužbo)*
English: These infections were due to bacteria, mycobacteria, fungi, viruses and parasites (including protozoa).
Slovenian: Te okužbe so povzročale bakterije, mikobakterije, glivice, virusi in paraziti (vključno s protozoji).
English: • Signs of autoimmune reactions (where antibodies are made that may harm normal tissues in the body) such as pain, itching, weakness, and abnormal breathing, thinking, sensation, or vision
Slovenian: • znaki avtoimunskih reakcij (reakcije, pri katerih se tvorijo protitelesa, ki lahko poškodujejo normalna telesna tkiva), kot so bolečina, srbenje, oslabelost, težave z dihanjem, motnje mišljenja, zaznavanja ali vida;
English: Please tell your doctor if you or the child in your care have a history of alcohol abuse.
Slovenian: Povejte zdravniku, če imate vi ali otrok, za katerega skrbite, zgodovino zlorabe alkohola.
English: In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with LIFMIOR developed injection site reactions compared with 3.4% of placebo-treated patients during the first 12 weeks of treatment.
Slovenian: V nadzorovanih preskušanjih bolnikov s psoriazo v plakih so se reakcije na mestu injiciranja v prvih 12 tednih zdravljenja pojavile pri približno 13,6 % bolnikov, zdravljenih z zdravilom LIFMIOR, in pri 3,4 % bolnikov, ki so dobivali placebo.
English: Worsening of cardiac failure congestive (see section 4.4)
Slovenian: Srčne bolezni poslabšanje kongestivnega srčnega popuščanja (glejte poglavje 4.4)
English: Push the open end of the pen firmly against the skin, so that the needle safety shield is pushed completely inside of the pen.
Slovenian: Pritisnite odprti konec peresnika čvrsto navzdol proti koži, da varnostni ščit igle ne bo več viden.
English: From the start of part 2, the median time to flare was ≥ 116 days for patients who received LIFMIOR and 28 days for patients who received placebo.
Slovenian: Od začetka drugega dela študije je bil mediani čas do ponovnega izbruha bolezni  116 dni pri bolnikih na zdravilu LIFMIOR in 28 dni pri bolnikih na placebu.
English: This combination has not demonstrated increased clinical benefit; such use is not recommended (see section 4.4).
Slovenian: Ta kombinacija ni pokazala povečane klinične koristi, zato njena uporaba ni priporočljiva (glejte poglavje 4.4).
English: Patients were observed off treatment for the occurrence of rebound (PASI ≥150% of baseline) and for the time to relapse (defined as a loss of at least half of the improvement achieved between baseline and week 24).
Slovenian: Bolnike so brez zdravljenja spremljali glede preobratnih znakov (PASI  150 % izhodiščnega) in časa do recidiva (opredeljenega kot izginotje vsaj polovice izboljšanja, doseženega med izhodiščem in 24. tednom).
English: The long-term safety of LIFMIOR in combination with other disease-modifying antirheumatic drugs (DMARD) has not been established.
Slovenian: Varnost dolgotrajnega kombiniranega zdravljenja z zdravilom LIFMIOR in drugimi imunomodulirajočimi antirevmatičnimi zdravili (DMARD - Disease-Modifying AntiRheumatic Drugs) ni bila ugotovljena.
English: 0.8†,φ a: Patients who did not complete 12 months in the study were considered to be non-responders.
Slovenian: HAQ v izhodišču po 52 tednih a: Bolniki, ki v študiji niso sodelovali 12 mesecev, so bili obravnavani kot neodzivni.
English: Undesirable effects in paediatric patients with plaque psoriasis In a 48-week study in 211 children aged 4 to 17 years with paediatric plaque psoriasis, the adverse events reported were similar to those seen in previous studies in adults with plaque psoriasis.
Slovenian: Neželeni učinki pri pediatričnih bolnikih s psoriazo v plakih V 48-tedenski študiji pri 211 otrocih, starih 4 do 17 let, z otroško psoriazo v plakih so bili poročani neželeni učinki podobni tistim, ki so jih opažali v predhodnih študijah pri odraslih s psoriazo v plakih.
English: Ankylosing Spondylitis Response
Slovenian: Odziv ankilozirajočega spondilitisa
English: LIFMIOR should be discarded if not used within four weeks after removal from the refrigerator.
Slovenian: Zdravilo LIFMIOR zavrzite, če ga ne porabite v štirih tednih po odvzemu iz hladilnika.
English: After 12 weeks of treatment, patients in the placebo group began treatment with blinded LIFMIOR (25 mg twice a week); patients in the active treatment groups continued to week 24 on the dose to which they were originally randomised.
Slovenian: Po 12 tednih zdravljenja so bolniki v skupini s placebom začeli slepo zdravljenje z zdravilom LIFMIOR (25 mg dvakrat na teden), bolniki v skupinah z aktivnim zdravljenjem pa so do 24. tedna nadaljevali z odmerkom, na katerega so bili prvotno randomizirani.
English: Histiocytosis haematophagic (macrophage activation syndrome)*
Slovenian: hematofagna histiocitoza (sindrom aktivacije makrofagov)*
English: Be careful not to bend or twist the cover during removal to avoid damage to the needle.
Slovenian: Pazite, da med odstranjevanjem pokrovčka le-tega ne ukrivite ali zavihate, da ne poškodujete igle.
English: Radiographs of hands and wrists were obtained at baseline and months 6, 12, and 24.
Slovenian: Radiografijo dlani in zapestja so opravili v izhodišču in v 6., 12. in 24. mesecu.
English: In a double blind, placebo controlled, randomised clinical study in adult patients with psoriatic arthritis 184 patients also received a multivalent pneumococcal polysaccharide vaccine at week 4.
Slovenian: V dvojno slepi s placebom nadzorovani randomizirani klinični študiji pri odraslih bolnikih s psoriatičnim artritisom je 184 bolnikov v 4. tednu dobilo tudi multivalentno polisaharidno cepivo proti pnevmokokom.
English: TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on cross-linking of cell surface TNFRs.
Slovenian: TNF in limfotoksin obstajata pretežno v obliki homotrimerov, njuna biološka aktivnost pa je odvisna od navzkrižne vezave na receptorje TNF na površini celice.
English: For patients who received 25 mg twice weekly throughout the study, the PASI 75 response continued to improve between weeks 12 and 36.
Slovenian: Pri bolnikih, ki so dobivali 25 mg dvakrat na teden ves čas študije, se je odziv PASI 75 med 12. in 36. tednom še naprej izboljševal.
English: These mean concentrations in patients with paediatric plaque psoriasis were similar to the concentrations observed in patients with juvenile idiopathic arthritis (treated with 0.4 mg/kg etanercept twice weekly, up to maximum dose of 50 mg per week).
Slovenian: Te povprečne koncentracije pri bolnikih s pediatrično psoriazo v plakih so bile podobne koncentracijam, ki so jih opazili pri bolnikih z juvenilnim idiopatskim artritisom (zdravljenih z 0,4 mg/kg etanercepta dvakrat na teden, do največjega odmerka 50 mg na teden).
English: • To break the seal, bend the larger end down and then up until broken (see Diagram 13).
Slovenian: Plombo prelomite tako, da upognete daljši del brizge navzdol in nato navzgor, dokler se ne prelomi (glejte sliko 13).
English: Do not use LIFMIOR
Slovenian: Ne uporabljajte zdravila LIFMIOR
English: Patients weighing 62.5 kg or more, may be dosed using a fixed-dose pre-filled syringe or pre-filled pen.
Slovenian: Bolnikom, ki tehtajo 62,5 kg ali več, lahko dajemo odmerke zdravila z napolnjeno injekcijsko brizgo ali napolnjenim injekcijskim peresnikom s stalnim odmerkom.
English: This section presents data from four randomised controlled trials in adults with rheumatoid arthritis, one study in adults with psoriatic arthritis, one study in adults with ankylosing spondylitis, one study in adults with non-radiographic axial spondyloarthritis, four studies in adults with plaque psoriasis, three studies in juvenile idiopathic arthritis and one study in paediatric patients with plaque psoriasis.
Slovenian: V tem poglavju so prikazani podatki iz štirih randomiziranih nadzorovanih preskušanj pri odraslih z revmatoidnim artritisom, ene študije pri odraslih s psoriatičnim artritisom, ene študije pri odraslih z ankilozirajočim spondilitisom, ene študije pri odraslih z radiografsko nezaznavnim aksialnim spondilartritisom, štirih študij pri odraslih s psoriazo v plakih, treh študij pri bolnikih z juvenilnim idiopatskim artritisom in ene študije pri otrocih s psoriazo v plakih.
English: Pancytopenia and aplastic anaemia
Slovenian: Pancitopenija in aplastična anemija
English: Serious haematological, neurological and autoimmune reactions have also been reported.
Slovenian: Poročali so tudi o pojavu resnih hematoloških, nevroloških in avtoimunskih neželenih učinkov.
English: Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate.
Slovenian: Zdravljenje aktivnega in progresivnega psoriatičnega artritisa pri odraslih, če je bil odziv na zdravljenje z imunomodulirajočimi antirevmatičnimi zdravili nezadosten.
English: This section presents data from three studies in juvenile idiopathic arthritis, one study in paediatric patients with plaque psoriasis, four studies in adults with rheumatoid arthritis, and four studies in adults with plaque psoriasis.
Slovenian: V tem poglavju so prikazani podatki iz treh študij pri bolnikih z juvenilnim idiopatskim artritisom, ene študije pri otrocih s psoriazo v plakih, štirih študij pri odraslih z revmatoidnim artritisom in štirih študij pri odraslih s psoriazo v plakih.
English: In studies when adult patients received concurrent treatment with LIFMIOR plus anakinra, a higher rate of serious infections compared to LIFMIOR alone was observed and 2% of patients (3/139) developed neutropenia (absolute neutrophil count < 1000/mm3).
Slovenian: V študijah, v katerih so odrasli bolniki sočasno prejemali zdravilo LIFMIOR in anakinro, so opažali večjo stopnjo resnih okužb v primerjavi s samim zdravilom LIFMIOR in pri 2 % bolnikov (3/139) se je pojavila nevtropenija (absolutna koncentracija nevtrofilcev < 1.000/mm
English: Radiographs of hands/wrists and feet were read at baseline and 6, 12, and 24 months.
Slovenian: Radiografske slike dlani in zapestij ter stopal so ocenili v izhodišču in po 6, 12 in 24 mesecih.
English: How to use LIFMIOR
Slovenian: Kako uporabljati zdravilo LIFMIOR
English: This combination has not demonstrated increased clinical benefit; such use is not recommended (see section 4.5).
Slovenian: Ta kombinacija ni pokazala povečane klinične koristi, zato njena uporaba ni priporočljiva (glejte poglavje 4.5).
English: If any of the following happen to the child, do not give the child more LIFMIOR.
Slovenian: Če se pri otroku pojavi karkoli od naslednjega, mu zdravila LIFMIOR ne smete več dajati.
English: In part 2, 6 of 25 (24%) patients remaining on LIFMIOR experienced a disease flare compared to 20 of 26 (77%) patients receiving placebo (p=0.007).
Slovenian: V drugem delu je 6 od 25 (24 %) bolnikov, ki so ostali na zdravilu LIFMIOR, doživelo ponoven izbruh bolezni, v primerjavi z 20 od 26 (77 %) bolnikov, ki so v drugem delu prejemali placebo (p = 0,007).
English: Serious allergic/anaphylactic reactions (including angioedema, bronchospasm), sarcoidosis
Slovenian: resne alergijske/ anafilaktične reakcije (vključno z angioedemom in bronhospazmom), sarkoidoza poslabšanje simptomov dermatomiozitisa
English: In clinical studies, concurrent administration of abatacept and LIFMIOR resulted in increased incidences of serious adverse events.
Slovenian: V kliničnih študijah je sočasna uporaba abatacepta in zdravila LIFMIOR zvečala pojavnost resnih neželenih učinkov.
English: The highest dose level evaluated has been an intravenous loading dose of 32 mg/m2 followed by subcutaneous doses of 16 mg/m2 administered twice weekly.
Slovenian: Največje ocenjeno odmerjanje je bilo: intravenski polnilni odmerek 32 mg/m2, nato pa 16 mg/m2 2-krat tedensko subkutano.
English: • A needle-free demonstration device
Slovenian: • peresnik brez igle za prikaz uporabe
English: You can help by reporting any side effects you may get.
Slovenian: Tudi sami lahko k temu prispevate tako, da poročate o kateremkoli neželenem učinku zdravila, ki bi se utegnil pojaviti pri vas.
English: Additionally, studies have not been conducted to assess the effects of discontinuing or reducing the recommended dose of LIFMIOR following its long-term use in patients with JIA.
Slovenian: Pri bolnikih z JIA prav tako niso izvedli študij za ovrednotenje učinka prekinitve zdravljenja ali zmanjšanja priporočenega odmerka zdravila LIFMIOR po njegovi dolgotrajni uporabi.
English: The study evaluated 215 adult patients (modified intent-to-treat population) with active nr-AxSpa (18 to 49 years of age), defined as those patients meeting the ASAS classification criteria of axial spondyloarthritis but did not meet the modified New York criteria for AS.
Slovenian: V študiji so ocenili 215 odraslih bolnikov (spremenjena populacija, ki so jo nameravali zdraviti) z aktivnim nr-AxSpa (starih od 18 do 49 let), opredeljenih kot bolniki, ki izpolnjujejo merila ASAS za razvrstitev aksialnega spondilartritisa, ki pa niso ustrezali spremenjenim newyorškim merilom za AS. Bolniki so morali imeti tudi nezadostni odziv na vsaj dva NSAID ali intoleranco zanju.
English: Some have occurred within a few weeks after initiating treatment with LIFMIOR in patients who have underlying conditions (e.g., diabetes, congestive heart failure, history of active or chronic infections) in addition to their rheumatoid arthritis (see section 4.4).
Slovenian: Nekatere okužbe so se pojavile nekaj tednov po začetku zdravljenja bolnikov, ki so imeli poleg revmatoidnega artritisa tudi druga obolenja (npr. sladkorno bolezen, kongestivno srčno popuščanje, aktivne ali kronične okužbe v anamnezi) (glejte poglavje 4.4).
English: L-Arginine hydrochloride Sodium phosphate monobasic dihydrate Sodium phosphate dibasic dihydrate Water for injections
Slovenian: L-argininijev klorid natrijev dihidrogenfosfat dihidrat natrijev hidrogenfosfat dihidrat voda za injekcije
English: Additionally, there have been rare reports of peripheral demyelinating polyneuropathies (including Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, demyelinating polyneuropathy, and multifocal motor neuropathy).
Slovenian: Poleg tega so redko poročali o perifernih demielinizirajočih polinevropatijah (vključno z Guillain-Barréjevim sindromom, kronično vnetno demielinizirajočo polinevropatijo, demielinizirajočo polinevropatijo in multifokalno motorično nevropatijo).
English: In the toxicological studies with LIFMIOR, no dose-limiting or target organ toxicity was evident.
Slovenian: V študijah toksičnosti zdravila LIFMIOR ni bilo opaziti toksičnosti, ki bi omejevala odmerjanje, niti toksičnosti za tarčne organe.
English: • While holding the vial in one hand, remove the plastic packaging from the vial adaptor (see Diagram 5).
Slovenian: Z eno roko še vedno držite vialo, z drugo pa odstranite plastično embalažo z adapterja (glejte sliko 5).
English: b. One cotton ball or gauze
Slovenian: b. Eno vato ali gazo.
English: LIFMIOR is supplied with pre-filled syringes containing water for injection.
Slovenian: Zdravilu LIFMIOR je priložena napolnjena injekcijska brizga, ki vsebuje vodo za injekcije.
English: However, limited safety data from a patient registry suggest that the safety profile in children from 2 to 3 years of age is similar to that seen in adults and children aged 4 years and older, when dosed every week with 0.8 mg/kg subcutaneously (see section 5.1).
Slovenian: Vendar pa omejeni podatki o varnosti iz registra bolnikov nakazujejo, da je pri subkutani uporabi zdravila v odmerku 0,8 mg/kg enkrat na teden pri otrocih, starih od 2 do 3 let, varnostni profil podoben profilu pri odraslih in otrocih, starih 4 leta in več (glejte poglavje 5.1).
English: Do NOT remove the grey stopper or aluminium ring around the top of the vial.
Slovenian: Z vrha viale NE odstranjujte sivega gumijastega zamaška niti aluminijastega obročka.
English: Patients were between 18 and 70 years of age and had active psoriatic arthritis (≥ 3 swollen joints and ≥ 3 tender joints) in at least one of the following forms: (1) distal interphalangeal (DIP) involvement; (2) polyarticular arthritis (absence of rheumatoid nodules and presence of psoriasis); (3) arthritis mutilans; (4) asymmetric psoriatic arthritis; or (5) spondylitis-like ankylosis.
Slovenian: Starost bolnikov je bila od 18 do 70 let in vsi so imeli aktivni psoriatični artritis (≥ 3 otekli sklepi in ≥ 3 občutljivi sklepi) v najmanj eni od naslednjih oblik: (1) distalna interfalangealna prizadetost (DIP); (2) poliartikularni artritis (odsotnost revmatoidnih nodulov in prisotnost psoriaze); (3) artritis mutilans; (4) asimetrični psoriatični artritis ali (5) spondilitisu podobna ankiloza.